Catalyst Pharmaceuticals (CPRX) Competitors

Catalyst Pharmaceuticals (NASDAQ:CPRX) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, earnings and media sentiment.

Does the media refer more to CPRX or BPMC?

In the previous week, Catalyst Pharmaceuticals had 2 more articles in the media than Blueprint Medicines. MarketBeat recorded 7 mentions for Catalyst Pharmaceuticals and 5 mentions for Blueprint Medicines. Catalyst Pharmaceuticals' average media sentiment score of 1.55 beat Blueprint Medicines' score of 1.33 indicating that Catalyst Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Catalyst Pharmaceuticals	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Blueprint Medicines	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is CPRX or BPMC more profitable?

Catalyst Pharmaceuticals has a net margin of 36.91% compared to Blueprint Medicines' net margin of -27.70%. Catalyst Pharmaceuticals' return on equity of 42.45% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Catalyst Pharmaceuticals	36.91%	42.45%	36.59%
Blueprint Medicines	-27.70%	-64.60%	-17.22%

Which has stronger earnings and valuation, CPRX or BPMC?

Catalyst Pharmaceuticals has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Catalyst Pharmaceuticals	$534.65M	4.83	$163.89M	$1.57	13.49
Blueprint Medicines	$562.12M	14.86	-$67.09M	-$2.47	-52.35

Which has more volatility and risk, CPRX or BPMC?

Catalyst Pharmaceuticals has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.89, meaning that its share price is 11% less volatile than the S&P 500.

Do analysts recommend CPRX or BPMC?

Catalyst Pharmaceuticals presently has a consensus price target of $32.83, suggesting a potential upside of 54.99%. Blueprint Medicines has a consensus price target of $128.25, suggesting a potential downside of 0.82%. Given Catalyst Pharmaceuticals' stronger consensus rating and higher probable upside, equities research analysts clearly believe Catalyst Pharmaceuticals is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Catalyst Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Blueprint Medicines	0 Sell rating(s)	17 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.24

Do insiders & institutionals have more ownership in CPRX or BPMC?

79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 10.4% of Catalyst Pharmaceuticals shares are held by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Summary

Catalyst Pharmaceuticals beats Blueprint Medicines on 14 of the 17 factors compared between the two stocks.